Monoclonal antibody development service by mouse hybridoma technology
This service includes immunization of mice with immunogenes, following by hybridoma generation, screening and subcloning, antibody production in hybridoma cell culture, purification and characterization.
We develop antibodies against KLH (or other carrier) conjugated peptides, recombinant proteins, and other available immunogenes. We recommend the use of recombinant proteins due to stronger immune response and availability of larger number of epitopes when compared with peptide immunization.
The service includes the following steps:
Immunization takes approximately 90 to 120 days. For generation of high-affinity antibodies, repeated exposure to antigen is recommended. Affinity-maturation significantly increases affinity of the antibody.
After successful immunization, hybridoma culture is generated, where mouse spleen cells are fused with mouse myeloma SP2-0 culture cells. Within 10-14 days, the surviving hybridoma cultures are screened by the ELISA assay in antigen recognition. Up to 5 clones will be expanded, cryopreserved, and delivered to the client.
Additionally, subcloning of hybridoma clones can be performed, and antibodies could be produced in different scales, purified and characterized.